Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 25, 2011

View Archived Issues

Study finds biomarkers of metastatic disease progression in prostate cancer

Therapy benefits children with Tay-Sachs and Sandhoff's diseases / News in Context

Phase II and III data presented on vorinostat

Xencor commences phase I study of immunotherapy for autoimmune diseases

AMG-827 improves quality of life in patients with plaque psoriasis

Phase III trial shows safety/tolerability of BG-12 in MS

FDA approves adjunctive therapy for Lennox-Gastaut syndrome

Adolor to be acquired by Cubist Pharmaceuticals

Mesoblast clear to begin phase II stem cell therapy trial for wet AMD

CHMP maintains earlier opinion after reexamining Glybera MAA

New phosphodiesterase 10A inhibitors prepared by Roche

Novartis provides update on regulatory timelines for NVA-237 and QVA-149

Novel B-raf inhibitors disclosed by Boehringer Ingelheim

Ajinomoto presents new factor Xa inhibitors

CHMP issues opinion on approval of Bronchitol

Vertex begins global phase IIIb Incivek combination study

Novel spider venom-derived contraceptive peptides designed in Chile

FDA to discuss Alexza Pharmaceuticals' NDA for Adasuve

Neuralstem receives FDA approval to advance ongoing ALS trial

Gilead and GlobeImmune enter HBV vaccine collaboration

Cell Therapeutics resubmits pixantrone NDA

Study establishes hENT1 cutoff level for LEAP trial

FDA advisory committee to review Affymax's peginesatide NDA

Karo Bio to spin off preclinical activities

MolMed expands phase III trial of NGR-hTNF

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 16, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for June 16, 2026
EHA 2026: With new lenses, a changing view on pediatric cancers
BioWorld
In the most simplistic view, adult cancers occur because “immature cells are exposed to mutagens, accumulate mutations, and across life ultimately transform into...
Anti-C5aR1 antibodies linked to outcomes in giant cell arteritis
BioWorld Science
More effective glucocorticoid-sparing therapies are needed for the treatment of giant cell arteritis (GCA). Studies found that complement signaling pathways...
Fortvita and Innovent patent new anti-TROP2/B7-H4 ADCs
BioWorld Science
Fortvita Biologics Inc. and Innovent Biologics (Suzhou) Co. Ltd. have jointly reported new antibody-drug conjugates (ADCs) comprising a bispecific antibody or...